ArticleAmerican journal of cancer research2016
Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma.
Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 68 citations in OpenAlex.
- Exploring NNMT: from metabolic pathways to therapeutic targets.Archives of pharmacal research · 2024Review
- Uncovering Metabolic Alterations in HCT-116 Colon Cancer Cells upon Exposure to Bamboo Leaf Extract Obtained fromMolecules (Basel, Switzerland) · 2024Article
- Knockdown of nicotinamide N-methyltransferase suppresses proliferation, migration, and chemoresistance of Merkel cell carcinoma cells in vitro.Human cell · 2024Article
- Gastric Cancer in the Era of Epigenetics.International journal of molecular sciences · 2024Review
- Inhibitors of NADInternational journal of molecular sciences · 2024Review
- NNMT overexpression is an adverse prognostic factor in uterine leiomyosarcoma.Turkish journal of medical sciences · 2024Article
- Review
- Characteristic Analysis of Featured Genes Associated with Cholangiocarcinoma Progression.Biomedicines · 2023Article
- Identification of an energy metabolism-related six-gene signature for distinguishing and forecasting the prognosis of low-grade gliomas.Annals of translational medicine · 2023Article
- NNMT Is an Immune-Related Prognostic Biomarker That Modulates the Tumor Microenvironment in Pan-Cancer.Disease markers · 2023Article
- NicotinamideBiomolecules · 2022Review
- Systematic pan-cancer analysis of the nicotinamide n-methyltransferase in human cancer.Frontiers in genetics · 2022Article
- Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy.Frontiers in oncology · 2022Review
- OSgc: A Web Portal to Assess the Performance of Prognostic Biomarkers in Gastric Cancer.Frontiers in oncology · 2022Article
- Prognostic value of nicotinamideOpen medicine (Warsaw, Poland) · 2022Article
- Drug metabolism-related eight-gene signature can predict the prognosis of gastric adenocarcinoma.Journal of clinical laboratory analysis · 2021Article
- Methylosystem for Cancer Sieging Strategy.Cancers · 2021Review
- Macrocyclic peptides as allosteric inhibitors of nicotinamideRSC chemical biology · 2021Article
- Review
- The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In clinical practice, cancer stage (or grade) and some biomarkers, such as carcinoembryonic antigen (CEA) and CA199, are widely used to predict the prognosis of gastric carcinoma patients. Due to the limited role of prognostic indicators for gastric carcinoma, this condition remains one of the most fatal human malignancies with a dismal prognosis. Nicotinamide N-methyltransferase (NNMT, EC.2.1.1.1), a metabolizing enzyme, is involved in the development and progression of various carcinomas. However, the prognostic and biological functions of NNMT in gastric carcinoma are not yet clear. In the present study, NNMT was found to be overexpressed at the mRNA and protein levels in gastric carcinoma tissues compared with adjacent tissues. Importantly, the survival analysis verified that NNMT expression is an independent prognostic factor for overall survival of gastric cancer patients. Moreover, NNMT expression was related to primary tumor size, lymph node metastasis, distant metastasis, and TNM (tumor, node, and metastasis) stage. We also demonstrated that knockdown of NNMT inhibits cellular proliferation, invasion and migration in vitro and in vivo. Overall, the results of this study suggest that NNMT is a promising prognostic predictor for gastric cancer patients and could be used as a new target for gastric cancer therapy.
Indexed as
Identifiers
27152242PMC4851844W2416773597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.